ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
|
|
- Brook Daniel
- 5 years ago
- Views:
Transcription
1 ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 SCOPE OF THE STUDY 2 METHODOLOGY AND INFORMATION SOURCES 3 ANALYST'S CREDENTIALS 3 RELATED BCC RESEARCH REPORTS 3 BCC RESEARCH WEBSITE 4 DISCLAIMER 4 CHAPTER 2 EXECUTIVE SUMMARY 6 EXECUTIVE SUMMARY 6 SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, ($ 7 7 CHAPTER 3 INDUSTRY OVERVIEW 10 MAJOR DEVELOPMENTS 10 COAGULATION FACTORS TARGETED TO REDUCE CVD 10 DEVELOPMENT OF ANTIDOTES FOR THROMBIN INHIBITORS 10 Andexanet Alfa 10 Praxbind (Idarucizumab) 11 TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL 12 SALES PERFORMANCE OF MAJOR DRUGS PROJECTED THROUGH XARELTO (RIVAROXABAN) 12 ELIQUIS (APIXABAN) 12 PRADAXA (DABIGATRAN ETEXILATE MESYLATE) 13 LOVENOX (ENOXAPARIN) 13 PLAVIX (CLOPIDOGREL) 13 TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 ($ PATENT ANALYSIS 14 PATENT BY ASSIGNEE 14 FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN TO APRIL 2016 FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN TO APRIL 2016 EPIDEMIC OF CARDIOVASCULAR DISEASE 17 TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES 18 RISK FACTORS AND PREVENTION OF CVD 20 CLASSIFICATION OF CARDIOVASCULAR DISEASES 20 CORONARY HEART DISEASE 20 Prevalence of CHD in the U.S. 21 TABLE 4 CORONARY HEART DISEASE PROFILE 21 TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY,
3 ACUTE MYOCARDIAL INFARCTION 23 TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE 24 THE CIRCULATORY SYSTEM 25 BLOOD VESSEL STRUCTURE 25 BLOOD FLOW 26 CONDITIONS 27 THROMBUS 27 EMBOLUS 28 ALTERATIONS IN VENOUS FLOW 29 DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM 29 TABLE 7 VIRCHOW S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM HEMOSTASIS (THE CLOTTING PROCESS) 31 DISEASES ASSOCIATED WITH THROMBOEMBOLISM 32 ACUTE CORONARY SYNDROME 32 ISCHEMIC HEART DISEASE 32 Etiology 33 Mechanisms of Coronary Atherosclerosis 33 Pathophysiology of Ischemia 34 ANGINA PECTORIS 35 CHRONIC ISCHEMIC CARDIOMYOPATHY 35 SUDDEN CARDIAC DEATH 35 ATRIAL FIBRILLATION 36 Causes 36 CEREBROVASCULAR DISEASE 37 STENT THROMBOSIS 38 DEMOGRAPHICS 39 TABLE 8 GLOBAL POPULATION BY SELECTED REGION, ( 39 TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, (AVERAGE PERCENTAGE GROWTH PER YEAR) FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, (AVERAGE PERCENTAGE GROWTH) CV, VTE, AF AND STROKE DEMOGRAPHICS 42 Venous Thromboembolism 42 Venous Thromboembolism and Lifestyle 43 Venous Thromboembolism and Air Travel CHAPTER 4 ANTICOAGULANTS 47 OVERVIEW 47 PRODUCTS 48 LOW MOLECULAR WEIGHT HEPARIN 48 Lovenox 48 TABLE 10 LOVENOX DRUG LABEL 49 Fragmin 50 TABLE 11 FRAGMIN DRUG LABEL 50 Innohep 52 TABLE 12 INNOHEP DRUG LABEL 52 Orgaran 53
4 TABLE 13 ORGARAN DRUG LABEL 54 Normiflo 55 TABLE 14 NORMIFLO DRUG LABEL 56 Embolex 56 TABLE 15 EMBOLEX DRUG LABEL 57 Fraxiparine 57 TABLE 16 FRAXIPARINE DRUG LABEL 58 Ariven/Arteven 58 TABLE 17 ARIVEN/ARTEVEN DRUG LABEL 59 ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) 59 GLOBAL MARKET FORECAST 60 TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, ($ MARKET BY GEOGRAPHIC REGION 62 TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 MARKET BY DRUG TYPE 64 TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 ($ TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 ($ FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, ($ TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, COMPETITIVE ANALYSIS 68 TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, CHAPTER 5 ANTIPLATELETS 71 OVERVIEW 71 PRODUCTS 71 ORAL ANTIPLATELETS 71 Plavix 71 TABLE 27 PLAVIX DRUG LABEL 71 Pletal 72
5 TABLE 28 PLETAL DRUG LABEL 73 Effient 74 TABLE 29 EFFIENT DRUG LABEL 74 Ticlid 75 Brilinta 75 TABLE 30 BRILINTA DRUG LABEL 75 IV ANTIPLATELETS 76 Integrilin 76 TABLE 31 INTEGRILIN DRUG LABEL 77 Aggrastat 78 TABLE 32 AGGRASTAT DRUG LABEL 78 ReoPro 79 TABLE 33 REOPRO DRUG LABEL 80 GLOBAL MARKET FORECAST 80 TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, ($ MARKET BY GEOGRAPHIC REGION 82 TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 MARKET BY DRUG TYPE 84 TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 ($ FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, ($ TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, COMPETITIVE ANALYSIS 88 TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, CHAPTER 6 THROMBIN INHIBITORS 91 OVERVIEW 91 PRODUCTS 91 DIRECT THROMBIN INHIBITORS 91
6 Argatroban 91 Angiomax 91 Iprivask 91 Pradaxa 92 THROMBOLYTIC AGENTS 92 Thrombolytic Enzymes 92 Tissue Plasminogen Activators 93 Activase 93 Retavase 93 TNKase 93 ATryn 93 DIRECT FACTOR XA INHIBITORS 93 Xarelto 93 Betrixaban 94 Savaysa (Edoxaban) 94 Eliquis 94 GLOBAL THROMBIN INHIBITOR MARKET FORECAST 95 TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 ($ FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, ($ REGIONAL MARKET SHARES OF THROMBIN INHIBITORS 96 TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 MARKET BY DRUG TYPE 98 TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 ($ FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, ($ TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 ($ MILLIONS/%) FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 RESEARCH AND DEVELOPMENT 102 GLOBAL ANTICOAGULANT/ANTITHROMBOTIC MARKET FORECAST 104 TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($
7 FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, ($ TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 MARKET BY GEOGRAPHIC REGION 107 TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, ($ TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 COMPETITIVE ANALYSIS 110 TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, CHAPTER 7 COMPANY PROFILES 113 ABBOTT LABORATORIES 113 HISTORY 113 RECENT DEVELOPMENTS 114 PRODUCTS 114 LOCATIONS 114 CORPORATE MANAGEMENT 114 ARMETHEON INC. 114 HISTORY 114 PRODUCTS 115 RECENT DEVELOPMENTS 115 CORPORATE MANAGEMENT 115 ASTRAZENECA 115 HISTORY 115 PRODUCTS 115 RECENT DEVELOPMENTS 116 LOCATIONS 116 CORPORATE MANAGEMENT 116 BAXTER INTERNATIONAL 116 HISTORY 116 PRODUCTS 117
8 RECENT DEVELOPMENTS 117 LOCATIONS 117 CORPORATE MANAGEMENT 117 BAYER AG 117 HISTORY 117 PRODUCTS 118 RECENT DEVELOPMENTS 118 LOCATIONS 118 CORPORATE MANAGEMENT 118 BIOVASCULAR INC. 119 HISTORY 119 PRODUCTS 119 LOCATIONS 119 CORPORATE MANAGEMENT 119 BOEHRINGER INGELHEIM GMBH 119 HISTORY 120 PRODUCTS 120 RECENT DEVELOPMENTS 120 LOCATIONS 120 CORPORATE MANAGEMENT 120 BRISTOL-MYERS SQUIBB CO. 121 HISTORY 121 PRODUCTS 121 RECENT DEVELOPMENTS 121 LOCATIONS 121 CORPORATE MANAGEMENT 122 CSL BEHRING 122 HISTORY 122 PRODUCTS 122 RECENT DEVELOPMENTS 122 LOCATIONS 123 CORPORATE MANAGEMENT 123 DAIICHI SANKYO CO. LTD. 123 HISTORY 123 PRODUCTS 123 RECENT DEVELOPMENTS 124 LOCATIONS 124 CORPORATE MANAGEMENT 124 ELI LILLY 124 HISTORY 124 PRODUCTS 125 LOCATIONS 125 CORPORATE MANAGEMENT 125 EMISPHERE TECHNOLOGIES 125 HISTORY 126 PRODUCTS 126 CORPORATE MANAGEMENT 126
9 F. HOFFMANN-LA ROCHE AG 126 HISTORY 126 PRODUCTS 127 RECENT DEVELOPMENTS 127 LOCATIONS 127 CORPORATE MANAGEMENT 127 GENENTECH 127 HISTORY 128 PRODUCTS 128 LOCATIONS 128 CORPORATE MANAGEMENT 128 GLAXOSMITHKLINE 128 HISTORY 129 PRODUCTS 129 LOCATIONS 129 CORPORATE MANAGEMENT 129 JOHNSON & JOHNSON 129 HISTORY 130 PRODUCTS 130 RECENT DEVELOPMENTS 130 LOCATIONS 130 CORPORATE MANAGEMENT 130 LIGAND PHARMACEUTICALS INC. 130 HISTORY 131 PRODUCTS 131 LOCATIONS 131 CORPORATE MANAGEMENT 131 THE MEDICINES CO. 131 HISTORY 131 PRODUCTS 132 RECENT DEVELOPMENTS 132 CORPORATE MANAGEMENT 132 MERCK 132 HISTORY 132 PRODUCTS 133 LOCATIONS 133 CORPORATE MANAGEMENT 133 MERRION PHARMACEUTICALS LTD. 133 HISTORY 133 PRODUCTS 134 LOCATIONS 134 CORPORATE MANAGEMENT 134 MICROBIX BIOSYSTEMS INC. 134 HISTORY 134 PRODUCTS 134 LOCATIONS 135 CORPORATE MANAGEMENT 135
10 NOVARTIS 135 HISTORY 135 PRODUCTS 135 RECENT DEVELOPMENTS: 136 LOCATIONS 136 CORPORATE MANAGEMENT 136 ONO PHARMACEUTICAL CO. LTD. 136 HISTORY 136 PRODUCTS 137 LOCATIONS 137 CORPORATE MANAGEMENT 137 OTSUKA PHARMACEUTICAL CO. LTD. 137 HISTORY 137 PRODUCTS 138 RECENT DEVELOPMENTS 138 LOCATIONS 138 CORPORATE MANAGEMENT 138 PFIZER INC. 139 HISTORY 139 PRODUCTS 139 RECENT DEVELOPMENTS: 140 CORPORATE MANAGEMENT 140 PORTOLA PHARMACEUTICALS 140 HISTORY 140 PRODUCTS 140 RECENT DEVELOPMENTS 140 LOCATION 141 CORPORATE MANAGEMENT 141 REVO BIOLOGICS INC. 141 HISTORY 141 PRODUCTS 141 LOCATIONS 142 CORPORATE MANAGEMENT 142 SANOFI 142 HISTORY 142 PRODUCTS 142 LOCATIONS 144 CORPORATE MANAGEMENT 144 SANTA CRUZ BIOTECHNOLOGY INC. 144 HISTORY 144 PRODUCTS 144 LOCATIONS 144 CORPORATE MANAGEMENT 144 SERVIER LABORATORIES 145 HISTORY 145 LOCATIONS 145 CORPORATE MANAGEMENT 145
11 SHIRE PHARMACEUTICALS 145 HISTORY 145 PRODUCTS 146 LOCATIONS 146 CORPORATE MANAGEMENT 146 SUN PHARMACEUTICALS 146 HISTORY 146 PRODUCTS 147 RECENT DEVELOPMENTS 147 LOCATIONS 148 CORPORATE MANAGEMENT 148 TEVA PHARMACEUTICALS LTD. 148 HISTORY 148 PRODUCTS 148 RECENT DEVELOPMENTS 149 LOCATIONS 149 CORPORATE MANAGEMENT 149 CHAPTER 8 APPENDIX A: LIST OF PATENTS 151 TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL CHAPTER 9 APPENDIX B: DIRECTORY OF COMPANIES COVERED IN THIS REPORT 160
12 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL 12 TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2020 ($ TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES 18 TABLE 4 CORONARY HEART DISEASE PROFILE 21 TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE 24 TABLE 7 VIRCHOW S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION TO PULMONARY EMBOLISM TABLE 8 GLOBAL POPULATION BY SELECTED REGION, ( 39 TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, (AVERAGE PERCENTAGE GROWTH PER YEAR) TABLE 10 LOVENOX DRUG LABEL 49 TABLE 11 FRAGMIN DRUG LABEL 50 TABLE 12 INNOHEP DRUG LABEL 52 TABLE 13 ORGARAN DRUG LABEL 54 TABLE 14 NORMIFLO DRUG LABEL 56 TABLE 15 EMBOLEX DRUG LABEL 57 TABLE 16 FRAXIPARINE DRUG LABEL 58 TABLE 17 ARIVEN/ARTEVEN DRUG LABEL 59 TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 ($ TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 ($ TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) TABLE 27 PLAVIX DRUG LABEL 71 TABLE 28 PLETAL DRUG LABEL 73 TABLE 29 EFFIENT DRUG LABEL 74 TABLE 30 BRILINTA DRUG LABEL 75 TABLE 31 INTEGRILIN DRUG LABEL 77 TABLE 32 AGGRASTAT DRUG LABEL 78 TABLE 33 REOPRO DRUG LABEL 80 TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION,
13 TABLE HEADING TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 ($ TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 ($ TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 ($ TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 ($ MILLIONS/%) TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%) TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL
14 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, ($ FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN TO APRIL 2016 FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN TO APRIL 2016 FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, (AVERAGE PERCENTAGE GROWTH) FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, ($ FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, ($ FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, ($ FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, ($ FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, ($ FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, ($ FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, ($ FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, ($
15 FIGURE TITLE FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS,
Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017
Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationJAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationJournal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationBayer AG Investor Relations Leverkusen Germany Investor News. Not intended for U.S. and UK Media
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Initiates Xarelto (Rivaroxaban) Study in Patients with Non- Valvular Atrial
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationSupplemental New Drug Application for Rivaroxaban to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome also resubmitted
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Complete Response Submitted to U.S. FDA on Bayer s Rivaroxaban for the Reduction
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationINTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS
INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS HLC046C November 2014 Mary C. Patton Project Analyst ISBN: 1-56965-982-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationRivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationU.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE
U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE FOD029E January 2015 Mary Anne Crandall Project Analyst ISBN: 1-62296-005-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationBayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer submits application for marketing approval of rivaroxaban for patients
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationGASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationAdult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More informationWho uses these medications? Assessing Patients Who Take Blood-Altering Medications. 3 Types of Acute Coronary Syndromes. Platelet-Related Fatalities
Assessing Patients Who Take Blood-Altering Medications Ann Eshenaur Spolarich, RDH, PhD Herman Ostrow School of Dentistry of USC; Arizona School of Dentistry and Oral Health; University of Maryland Dental
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationCHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationAtrial Fibrillation - Pipeline Review, H1 2017
Report Information More information from: https://www.wiseguyreports.com/reports/1095866-atrial-fibrillation-pipeline-review-h1-2017 Atrial Fibrillation - Pipeline Review, H1 2017 Report / Search Code:
More informationBOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationUpdate overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2017) in consultation
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationAmerican College of Cardiology 66th Annual Scientific Session (ACC.17):
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific
More informationPlavix eliquis and aspirin
Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationThe effect of the direct oral anticoagulants (DOACs) on haemostasis tests.
The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. Emmanuel J Favaloro, Haematology, ICPMR, Pathology West, Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital (with
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationAspirin versus pradaxa
Search Search Aspirin versus pradaxa 14-12-2012 Dabigatran (Pradaxa): Good news on safety but caution still warranted. the risk of bleeding versus the risk. (Aspirin and other inhibitors of. 15-12-2008
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationPearls in Thrombosis. Alan Bell, MD, FCFP
Pearls in Thrombosis Alan Bell, MD, FCFP Staff Physician, Humber River Regional Hospital Assistant Professor, Department of Family and Community Medicine University of Toronto Alan Bell MD, FCFP Disclosures
More informationAntiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia
1 Antiplatelet and Anticoagulant Therapy Management Surrounding Regional Anesthesia Key Points: Neuraxial complications are extremely rare. Epidural hematomas are one possible complication of neuraxial
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationto a DOAC anticoagulants (DOACs) dosing of DOACs for various indications switching from a DOAC and switching
Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services } Identify the FDA approved direct oral anticoagulants (DOACs) } Distinguish the differences in the dosing of DOACs for various indications
More informationGLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
More informationPIONEER AF-PCI Study with Bayer s Xarelto Accepted as Late- Breaking Clinical Trial Presentation at AHA 2016
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American Heart Association
More informationManagement of antithrombotic agents before endoscopy 삼성서울병원소화기내과임상강사이세옥
Management of antithrombotic agents before endoscopy 삼성서울병원소화기내과임상강사이세옥 Risk vs Benefit Hemorrhage Thrombosis Hemorrhage rarely fatal, controlled by endoscoic therapeutic measures, TAE, operation Thrombotic
More informationAnalysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb. Tro Kalayjian Chief Medical Analyst Chimera Research Group
Analysing Apixaban: Potential Growth Driver for Pfizer and Bristol Myers Squibb Tro Kalayjian Chief Medical Analyst Chimera Research Group Prevalence of AFib in the US is expected to increase upwards of
More informationBayer s Xarelto (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Secondary Prevention of Acute Coronary Syndrome (ACS): Bayer s Xarelto (Rivaroxaban)
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationTitle Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines. Department.
Document Control Title Patients receiving dabigatran requiring emergency reversal for surgery or treatment of haemorrhage Guidelines Author Author s job title Pharmacist Directorate PCS - Department Version
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationCANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS
CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationTABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAntidotes to DOACs - what s the status?
Antidotes to DOACs - what s the status? Charles Marc Samama Professor and Chairman Department of Anaesthesia and Intensive Care Hotel-Dieu and Cochin University Hospitals Paris, France Disclosures Companies
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationCHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More information